株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

トキソプラズマ症:パイプライン製品の分析

Toxoplasmosis - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 302504
出版日 ページ情報 英文 41 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.76円で換算しております。
Back to Top
トキソプラズマ症:パイプライン製品の分析 Toxoplasmosis - Pipeline Review, H1 2017
出版日: 2017年06月27日 ページ情報: 英文 41 Pages
概要

トキソプラズマ症とは、トキソプラズマ寄生虫への感染により発症する疾患です。主な症状として、体中が痛んだり、リンパ節が腫れたり、頭痛・発熱・倦怠感が生じたりすることがあります。主なリスク要因には、HIV/AIDSや化学療法、免疫抑制剤などが含まれています。主な治療法として、抗マラリア薬や抗生物質などがあります。

当レポートでは、世界各国でのトキソプラズマ症治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

トキソプラズマ症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

トキソプラズマ症:企業で開発中の治療薬

トキソプラズマ症:大学/機関で研究中の治療薬

トキソプラズマ症:パイプライン製品の概況

  • 初期段階の製品

トキソプラズマ症:企業で開発中の製品

トキソプラズマ症:大学/機関で研究中の製品

トキソプラズマ症の治療薬開発に従事している企業

Turing Pharmaceuticals AG

トキソプラズマ症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 分子タイプ別

薬剤プロファイル

トキソプラズマ症:休止中のプロジェクト

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9448IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Toxoplasmosis - Pipeline Review, H1 2017, provides an overview of the Toxoplasmosis (Infectious Disease) pipeline landscape.

Toxoplasmosis is a disease that results from infection with the Toxoplasma gondii parasite. Symptoms include body aches, swollen lymph nodes, headache, fever and fatigue. Risk factors include HIV/AIDS, chemotherapy and immunosuppressant drugs. Treatment includes an antimalarial drug and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Toxoplasmosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Toxoplasmosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Toxoplasmosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Toxoplasmosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 2 molecules, respectively.

Toxoplasmosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Toxoplasmosis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Toxoplasmosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Toxoplasmosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Toxoplasmosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Toxoplasmosis (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Toxoplasmosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Toxoplasmosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Toxoplasmosis - Overview
    • Toxoplasmosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Toxoplasmosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Toxoplasmosis - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Novartis AG
    • Turing Pharmaceuticals AG
  • Toxoplasmosis - Drug Profiles
    • silver sulfadiazine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Histone Deacetylase for Toxoplasmosis and Other Parasitic Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Toxoplasmosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CDPK1 for Protozoal Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit DHFR for Toxoplasmosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • toxoplasmosis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • toxoplasmosis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • toxoplasmosis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • toxoplasmosis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRP-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TRP-012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TUR-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Toxoplasmosis - Dormant Projects
  • Toxoplasmosis - Product Development Milestones
    • Featured News & Press Releases
      • Feb 03, 2016: Turing Pharmaceuticals Provides Key Facts to Congressional Oversight Committee
      • Jan 22, 2016: Turing Pharmaceuticals to Testify at Congressional Hearing on Drug Pricing
      • Dec 18, 2015: Continued Availability of Daraprim (pyrimethamine)
      • Nov 24, 2015: Texas Becomes Latest State ADAP to Add Daraprim (pyrimethamine) to Formulary
      • Oct 13, 2015: Turing Pharmaceuticals Announces Improvements in Daraprim Accessibility and Affordability
      • Sep 25, 2015: Keller Rohrback Investigates Turing Pharmaceuticals for Alleged Daraprim Price Gouging
      • Sep 24, 2015: Turing Pharmaceuticals Issues Statement on Daraprim Price Reduction
      • Sep 18, 2015: Turing Pharmaceuticals Provides Update On Availability Of Daraprim
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Toxoplasmosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Toxoplasmosis - Pipeline by AbbVie Inc, H1 2017
  • Toxoplasmosis - Pipeline by Novartis AG, H1 2017
  • Toxoplasmosis - Pipeline by Turing Pharmaceuticals AG, H1 2017
  • Toxoplasmosis - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Toxoplasmosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top